Literature DB >> 21375680

Halenaquinone, a chemical compound that specifically inhibits the secondary DNA binding of RAD51.

Motoki Takaku1, Takashi Kainuma, Takako Ishida-Takaku, Shintaro Ishigami, Hidekazu Suzuki, Satoshi Tashiro, Rob W M van Soest, Yoichi Nakao, Hitoshi Kurumizaka.   

Abstract

Mutations and single-nucleotide polymorphisms affecting RAD51 gene function have been identified in several tumors, suggesting that the inappropriate expression of RAD51 activity may cause tumorigenesis. RAD51 is an essential enzyme for the homologous recombinational repair (HRR) of DNA double-strand breaks. In the HRR pathway, RAD51 catalyzes the homologous pairing between single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA), which is the central step of the HRR pathway. To identify a chemical compound that regulates the homologous-pairing activity of RAD51, in the present study, we screened crude extract fractions from marine sponges by the RAD51-mediated homologous-pairing assay. Halenaquinone was identified as an inhibitor of the RAD51 homologous-pairing activity. A surface plasmon resonance analysis indicated that halenaquinone directly bound to RAD51. Intriguingly, halenaquinone specifically inhibited dsDNA binding by RAD51 alone or the RAD51-ssDNA complex, but only weakly affected the RAD51-ssDNA binding. In vivo, halenaquinone significantly inhibited the retention of RAD51 at double-strand break sites. Therefore, halenaquinone is a novel type of RAD51 inhibitor that specifically inhibits the RAD51-dsDNA binding.
© 2011 The Authors. Journal compilation © 2011 by the Molecular Biology Society of Japan/Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21375680     DOI: 10.1111/j.1365-2443.2011.01494.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  22 in total

1.  Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.

Authors:  Carlos Rodrigo Gil Del Alcazar; Pavlina Krasimirova Todorova; Amyn A Habib; Bipasha Mukherjee; Sandeep Burma
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

Review 2.  Targeting the homologous recombination pathway by small molecule modulators.

Authors:  Fei Huang; Alexander V Mazin
Journal:  Bioorg Med Chem Lett       Date:  2014-05-06       Impact factor: 2.823

Review 3.  Synthetic Lethality through the Lens of Medicinal Chemistry.

Authors:  Samuel H Myers; Jose Antonio Ortega; Andrea Cavalli
Journal:  J Med Chem       Date:  2020-11-02       Impact factor: 7.446

4.  RECK impedes DNA repair by inhibiting the erbB/JAB1/Rad51 signaling axis and enhances chemosensitivity of breast cancer cells.

Authors:  Kun-Jing Hong; Ming-Chuan Hsu; Wen-Chun Hung
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

5.  An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.

Authors:  Brian Budke; Jay H Kalin; Michal Pawlowski; Anna S Zelivianskaia; Megan Wu; Alan P Kozikowski; Philip P Connell
Journal:  J Med Chem       Date:  2012-12-26       Impact factor: 7.446

Review 6.  DNA repair targeted therapy: The past or future of cancer treatment?

Authors:  Navnath S Gavande; Pamela S VanderVere-Carozza; Hilary D Hinshaw; Shadia I Jalal; Catherine R Sears; Katherine S Pawelczak; John J Turchi
Journal:  Pharmacol Ther       Date:  2016-02-16       Impact factor: 12.310

Review 7.  Recent Developments Using Small Molecules to Target RAD51: How to Best Modulate RAD51 for Anticancer Therapy?

Authors:  Brian Budke; Wei Lv; Alan P Kozikowski; Philip P Connell
Journal:  ChemMedChem       Date:  2016-10-26       Impact factor: 3.466

8.  Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51.

Authors:  Brian Budke; Werner Tueckmantel; Kelsey Miles; Alan P Kozikowski; Philip P Connell
Journal:  ChemMedChem       Date:  2019-04-17       Impact factor: 3.466

9.  Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.

Authors:  Wei Lv; Brian Budke; Michal Pawlowski; Philip P Connell; Alan P Kozikowski
Journal:  J Med Chem       Date:  2016-04-21       Impact factor: 7.446

10.  A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death.

Authors:  Duncan E Scott; Nicola J Francis-Newton; May E Marsh; Anthony G Coyne; Gerhard Fischer; Tommaso Moschetti; Andrew R Bayly; Timothy D Sharpe; Kalina T Haas; Lorraine Barber; Chiara R Valenzano; Rajavel Srinivasan; David J Huggins; Miyoung Lee; Amy Emery; Bryn Hardwick; Matthias Ehebauer; Claudio Dagostin; Alessandro Esposito; Luca Pellegrini; Trevor Perrior; Grahame McKenzie; Tom L Blundell; Marko Hyvönen; John Skidmore; Ashok R Venkitaraman; Chris Abell
Journal:  Cell Chem Biol       Date:  2021-03-03       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.